Treatment of resistant forms of systemic lupus erythematosus with a type I interferon inhibitor in the early access program
https://doi.org/10.14412/1996-7012-2023-2-72-76
Abstract
The article presents the results of treatment of patients with systemic lupus erythematosus (SLE), who, due to resistance to traditional regimens, for the first time in the Russian Federation were included in the early access program of the type I interferon inhibitor – anifrolumab. Clinical data and results of instrumental examinations of a patient with SLE on the background of 6-month therapy are presented.
About the Authors
I. A. Leineman
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Yana Andreevna Leineman
41, Kirochnaya Street, St. Petersburg 191015
R. R. Samigullina
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
41, Kirochnaya Street, St. Petersburg 191015
M. S. Shostak
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
41, Kirochnaya Street, St. Petersburg 191015
V. I. Mazurov
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
41, Kirochnaya Street, St. Petersburg 191015
References
1. Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-45. doi: 10.1136/annrheumdis2019-215089.
2. Gaidukova IZ, Mazurov VI, Inamova OV, et al. Disease activity and comorbidities in patients with systemic lupus erythematosus — what has changed in two decades? Russkii meditsinskii zhurnal. 2021;(7):13-6. (In Russ.).
3. Postal M, Vivaldo JF, Fernandez-Ruiz R, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020 Dec;67:87-94. doi: 10.1016/j.coi.2020.10.014.
4. Nasonov EL, Solov'ev SK. Prospects of pharmacotherapy of systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2014; 52(3):311-21. (In Russ.).
5. Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39. doi: 10.1080/19420862.2015.1007810.
6. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderateto-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-86. doi: 10.1002/art.39962.
7. The Government of the Russian Federation, Resolution №853 of June 1, 2021, Moscow, On Approval of the Rules for the Import of Medicines for Medical Use into the Russian Federation. http://static.government.ru/media/files/983ApRBoMmVTEctrRv9Z6PoQ6BlvVEbq.pdf
8. Morand EF, Furie R, Tanaka Y, et al. TULIP-2 Trial Investigators. Trial of Anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-21 doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
9. Van Vollenhoven R, Morand E, Furie R, et al. Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets [abstract]. Arthritis Rheumatol. 2022;74(suppl 9):0359.
Review
For citations:
Leineman IA, Samigullina RR, Shostak MS, Mazurov VI. Treatment of resistant forms of systemic lupus erythematosus with a type I interferon inhibitor in the early access program. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2023;17(2):72-76. (In Russ.) https://doi.org/10.14412/1996-7012-2023-2-72-76
Views:
625
Email this article 